Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 8, 2008, Pages 1978-1981

  Lu, Mong Liang ^a,b   Shen, Winston W ^a,b   Chen, Chun Hsin ^a,b  

^a TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Antipsychotics; Aripiprazole; Hyperprolactinemia; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROLEPTIC AGENT; PROLACTIN; RISPERIDONE; SULPIRIDE;

ADULT; AKATHISIA; ANXIETY DISORDER; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERPROLACTINEMIA; MENSTRUATION; MENTAL STRESS; NAUSEA; POSITIVE AND NEGATIVE SYNDROME SCALE; PROLACTIN BLOOD LEVEL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIDE EFFECT; SLEEP DISORDER; SYMPTOMATOLOGY; TREMOR;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; ANTIPSYCHOTIC AGENTS; CROSS-OVER STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERPROLACTINEMIA; MIDDLE AGED; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; QUINOLONES; RISPERIDONE; SCHIZOPHRENIA; SEVERITY OF ILLNESS INDEX; SULPIRIDE; YOUNG ADULT;

EID: 56449093569     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2008.09.016     Document Type: Article

References (36)

1. Baptista T., Molina M.G., Martinez J.L., de Quijada M., Calanche de Cuesta I., Acosta A., et al. Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy premenopausal women: relationship with body weight regulation. Pharmacopsychiatry 30 (1997) 256-262
2. Brown W.A., and Laughren T.P. Tolerance to the prolactin-elevating effect of neuroleptics. Psychiatry Res 5 (1981) 317-322
3. Bushe C., and Shaw M. Prevalence of hyperprolactinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psychopharmacol 21 (2007) 768-773
4. Byerly M., Suppes T., Tran Q.V., and Baker R.A. Clinical implications of antipsychotic-induced hyperprolactinemia in patients with schizophrenia spectrum or bipolar spectrum disorders: recent developments and current perspectives. J Clin Psychopharmacol 27 (2007) 639-661
5. Casey D.E., Carson W.H., Saha A.R., Liebeskind A., Ali M.W., Jody D., et al. Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study. Psychopharmacology (Berl) 166 (2003) 391-399
6. Chen C.H., Huang M.C., and Lu M.L. Aripiprazole resolves symptomatic hyperprolactinemia in a male schizophrenic patient. Prog Neuropsychopharmacol Biol Psychiatry 32 (2008) 893-894
7. Gruen P.H., Sachar E.J., Langer G., Altman N., Leifer M., Frantz A., et al. Prolactin responses to neuroleptics in normal and schizophrenic subjects. Arch Gen Psychiatry 35 (1978) 108-116
8. Guy W. (1976). Clinical global impression. ECDEU Assessment Manual for Psychopharmacology, Revised. Rockville, MD, National Institute of Mental Health.
9. Haddad P.M., and Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64 (2004) 2291-2314
10. Hirose T., Uwahodo Y., Yamada S., Miwa T., Kikuchi T., Kitagawa H., et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable side-effect profile. J Psychopharmacol 18 (2004) 375-383
11. Jordan S., Koprivica V., Chen R., Tottori K., Kikuchi T., and Altar C.A. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 441 (2002) 137-140
12. Kane J.M., Carson W.H., Saha A.R., McQuade R.D., Ingenito G.G., Zimbroff D.L., et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 63 (2002)
13. Kapur S., Langlois X., Vinken P., Megens A.A., De Coster R., and Andrews J.S. The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats. J Pharmacol Exp Ther 302 (2002) 1129-1134
14. Kapur S., and Mamo D. Half a century of antipsychotics and still a central role for dopamine D2 receptors. Prog Neuropsychopharmacol Biol Psychiatry 27 (2003) 1081-1090
15. Kapur S., and Remington G. Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient. Biol Psychiatry 50 (2001) 873-883
16. Kay S.R., Fiszbein A., and Opler L.A. The Positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13 (1987) 261-276
17. Kleinberg D.L., Davis J.M., de Coster R., Van Baelen B., and Brecher M. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol 19 (1999) 57-61
18. Kuroki T., Meltzer H.Y., and Ichikawa J. Effects of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J Pharmacol Exp Ther 288 (1999) 774-781
19. Kuruvilla A., Peedicayil J., Srikrishna G., Kuruvilla K., and Kanagasabapathy A.S. A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin Exp Pharmacol Physiol 19 (1992) 603-606
20. Lin S.K., and Chen C.K. Reversal of antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole: a case report. J Clin Psychiatry 67 (2006) 1307
21. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., and Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl 334 (1987) 1-100
22. Marder S.R., McQuade R.D., Stock E., Kaplita S., Marcus R., Safferman A.Z., et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 61 (2003) 123-136
23. Mauri M.C., Bravin S., Bitetto A., Rudelli R., and Invernizzi G. A risk-benefit assessment of sulpiride in the treatment of schizophrenia. Drug Saf 14 (1996) 288-298
24. Meltzer H.Y., and Fang V.S. The effect of neuroleptics on serum prolactin in schizophrenic patients. Arch Gen Psychiatry 33 (1976) 279-286
25. Mir A., Shivakumar K., Williamson R.J., McAllister V., O'Keane V., and Aitchison K.J. Change in sexual dysfunction with aripiprazole: a switching or add-on study. J Psychopharmacol 22 (2008) 244-253
26. Naber D., and Lambert M. Aripiprazole: a new atypical antipsychotic with a different pharmacological mechanism. Prog Neuropsychopharmacol Biol Psychiatry 28 (2004) 1213-1219
27. Natesan S., Reckless G.E., Nobrega J.N., Fletcher P.J., and Kapur S. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 31 (2006) 1854-1863
28. Paulzen M., and Gründer G. Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole. Int J Neuropsychopharmacol 10 (2007) 149-151
29. Rivera J.L., Lal S., Ettigi P., Hontela S., Muller H.F., and Friesen H.G. Effect of acute and chronic neuroleptic therapy on serum prolactin levels in men and women of different age groups. Clin Endocrinol (Oxf) 5 (1976) 273-282
30. Shapiro D.A., Renock S., Arrington E., Chiodo L.A., Liu L.X., Sibley D.R., et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28 (2003) 1400-1411
31. Shim J.C., Shin J.G., Kelly D.L., Jung D.U., Seo Y.S., Liu K.H., et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry 164 (2007) 1404-1410
32. Wahl R., and Ostroff R. Reversal of symptomatic hyperprolactinemia by aripiprazole. Am J Psychiatry 162 (2005) 1542-1543
33. Weiden P.J. Switching antipsychotics: an updated review with a focus on quetiapine. J Psychopharmacol 20 (2006) 104-118
34. Wieck A., and Haddad P.M. Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review. Br J Psychiatry 182 (2003) 199-204
35. Wolf J., and Fiedler U. Hyperprolactinemia and amenorrhea associated with olanzapine normalized after addition of aripiprazole. J Clin Pharm Ther 32 (2007) 197-198
36. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 284 (2000) 3043-3045